As of November 6, 2026, 4D Molecular Therapeutics, Inc. is a publicly traded company (Nasdaq: FDMT); its largest reported holder is Janus Henderson, with 10.3% on Schedule 13G/A of April 7, 2026, then BVF Partners (9.99%) (Schedule 13G/A, April 7, 2026).
Is this your company?
About to sign with, pay or invest in 4D Molecular Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is 4D Molecular Therapeutics, Inc. a real, registered company?
- 4D Molecular Therapeutics, Inc. files with the SEC under CIK 1650648 (its SEC filings).
- Its shares are listed under the ticker FDMT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Emeryville, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under 4D MOLECULAR THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Kristian Humer, Principal Accounting Officer (Form 8-K filed 2026-03-30). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RA Capital (filed 2026-05-15).
Who are 4D Molecular Therapeutics, Inc.'s owners and officers?
4D Molecular Therapeutics, Inc.: incorporated in Delaware; business address in Emeryville, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-05-15).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-15 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2026-05-15 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 5.3% |
| Schedule 13G/A, 2026-04-07 | Janus Henderson Group PLC | 10.3% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Novo Holdings A/S | 6.4% |
| Schedule 13G, 2026-02-17 | Janus Henderson Group PLC | 8.1% |
| Schedule 13G/A, 2026-02-17 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2026-02-17 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G/A, 2026-02-09 | The Goldman Sachs Group, Inc. | 7.5% |
| Schedule 13G, 2025-10-20 | Novo Holdings A/S | 6.8% |
| Schedule 13G/A, 2025-10-17 | Blackrock, Inc. | 6.6% |
Questions about who owns 4D Molecular Therapeutics, Inc.
Who owns 4D Molecular Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of 4D Molecular Therapeutics, Inc.: Janus Henderson Group PLC (10.3%, Schedule 13G/A, filed 2026-04-07), Bvf Partners L P/Il (9.99%, Schedule 13G/A, filed 2026-05-15), Ra Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-05-15), The Goldman Sachs Group, Inc. (7.5%, Schedule 13G/A, filed 2026-02-09) and Blackrock, Inc. (6.6%, Schedule 13G/A, filed 2025-10-17); 2 more are listed above.
Who are the largest shareholders of 4D Molecular Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of 4D Molecular Therapeutics, Inc. on this page are Janus Henderson Group PLC (10.3%), Bvf Partners L P/Il (9.99%) and Ra Capital Management, L.P. (9.9%).
When did Janus Henderson Group PLC buy into 4D Molecular Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group PLC on this page is the Schedule 13G, filed 2026-02-17, reporting 8.1%; its latest, Schedule 13G/A filed 2026-04-07, reports 10.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on 4D Molecular Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 4D Molecular Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 4D Molecular Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-03-30 | Kristian Humer | Principal Accounting Officer | appointed |
Which insiders own 4D Molecular Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- RA Capital, a 10% owner: 4,563,211 shares (9.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2024-12-10).
- RA Capital Healthcare Fund LP, a 10% owner: 4,563,211 shares (9.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2024-12-10).
- , a 10% owner: 4,563,211 shares (9.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2024-12-10).
- , a 10% owner: 4,563,211 shares (9.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2024-12-10).
- , a director: 709,153 shares (1.4% of shares outstanding) (Form 4, 2026-10-07).
Shares outstanding: 49,778,127 as of 2024-02-23, from the company's latest SEC cover page.
How much has 4D Molecular Therapeutics, Inc. raised?
No fundraising or offering filing from 4D Molecular Therapeutics, Inc. is on file with us.
Keep reading
More on 4D Molecular Therapeutics, Inc. and the records around it.
4D Molecular Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Leadership changes Mar 2026
Companies that share a holder
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/4d-molecular-therapeutics